In the current study, 1 patient with NOTCH1-activating metastatic ACC and tumor BCL2 overexpression had additional tumor growth stabilization with the off-label addition of the BCL2 inhibitor Venetoclax to CB-103 after first progression. This evidence concerns the gene BCL2 and neoplasm.